Oligonucleotide Therapeutics Society
Recent Articles2026-08-24T06:57:48+00:00
12August, 2025

Behind the Rapid Development of an Individualized CRISPR Therapy for a Deadly Rare Disease

A baby is the first person to receive a bespoke CRISPR therapy designed specifically for him that directly fixes a disease-causing mutation in his genome. It wasn't long after KJ was born in the summer of 2024 that doctors noticed something was wrong. Within 48 hours, he was lethargic ...

31July, 2025

The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary

The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October 19–22, 2025, at the Budapest Congress Center in Budapest, Hungary. This premier global gathering of the oligonucleotide community is renowned for fostering dynamic, cross-disciplinary dialogue—bringing together leaders in chemistry, delivery, biology, immunology, ...

16July, 2025

OTS Member Highlight – Masad Damha, PhD

For Masad Damha, falling in love with science was easy. Growing up in Managua, Nicaragua, his high school teachers encouraged scientific exploration, curiosity, and experimentation, such as processing vegetable oil into soap, producing hydrogen and oxygen from water via electrolysis, and determining the gravitational force constant using a pendulum. ...

1July, 2025

Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease

Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, and more than 200,000 are at risk of inheriting it. The fatal disease often leaves a devastating family legacy, as ...

3June, 2025

NanoCas: A Newly Identified Compact Nuclease May Expand CRISPR’s Reach

The revolutionary CRISPR-Cas system has proven to be a precise method for genome editing, showing great promise in tackling genetic disorders. However, clinical trials for CRISPR-based treatments have faced delivery challenges due to the large size of the editing system. In the quest to overcome these limitations, researchers recently ...

13May, 2025

OTS Member Highlight – Holly Kordasiewicz, PhD

Holly Kordasiewicz was a curious, chatty child with a penchant for asking questions. At dinner, conversations were often about the fascinating things her mom, a registered nurse, learned at work, sparking Kordasiewicz's interest in medicine and biology. As her grandparents aged, and she witnessed neurodegenerative diseases gradually and relentlessly ...

The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary

July 31st, 2025|Categories: Perspectives on Current Science|

The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October 19–22, 2025, at the Budapest Congress Center in Budapest, Hungary. This premier ...

Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease

July 1st, 2025|Categories: Perspectives on Current Science|

Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, ...

Get the latest news!

  • Category

Go to Top